The U.S. Food and Drug Administration has authorized the use of PD-L1 expression and tumor mutational load as clinical prognostic indicators for survival in patients undergoing treatment with immune checkpoint inhibitors (ICIs) (4, 5). Here, CD274 is linked to neoplasm.